Navigation Links
Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
Date:10/27/2011

MOUNTAIN VIEW, Calif., Oct. 27, 2011 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will report financial results for the quarter ended September 30, 2011, on Monday, November 7, 2011, following the close of the U.S. financial markets.  On Monday, November 7, at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time, the Company will host an investor conference call and live webcast to provide a company update, as well as to discuss the financial results.  The conference call, live webcast and archived replay are open to all interested parties.

To access the conference call via the Internet, go to www.alexza.com, under the "Investor Relations" link.  Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required.  Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=PVXTMU3TM.

To access the live conference call via phone, dial 888-713-4199.  International callers may access the live call by dialing +1-617-213-4861.  The reference number to enter the call is 78230377.

The replay of the conference call may be accessed via the Internet, at www.alexza.com, or via phone at 888-286-8010 for domestic callers or +1-617-801-6888 for international callers.  The reference number for the replay of the call is 50703911.  A replay of the call will be available for two weeks following the event.

About Alexza Pharmaceuticals, Inc.

Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Research and Markets( http://www.researchandmarkets.com/research/45v9b3/urinary_slings ... Slings Market in the US 2015-2019" report to ... Slings market in the US to grow at a ... This report covers the present scenario and the growth ... for the period 2015-2019. To calculate the market size, ...
(Date:7/6/2015)... , July 6, 2015 Array BioPharma,s ... showcased this past weekend at the 2015 ESMO ... presentation.  At the meeting, data were shared from ... a 100-patient randomized Phase 2 expansion of that ... an EGFR inhibitor, with or without the addition ...
(Date:7/6/2015)... 2015 Akcea Therapeutics, a wholly-owned subsidiary ... announced today that the U.S. Food and Drug ... (ISIS-APOCIII Rx ) for the treatment of patients ... rare genetic disease characterized by extremely high triglyceride ... 2 study published in the NEJM in December ...
Breaking Medicine Technology:United States Urinary Slings Market 2015-2019 - Vaginal Slings (TVT, TOT, and Single-incision) & Male Slings (Artificial Urinary Sphincters) 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6
(Date:7/6/2015)... ... , ... The Asian-Pacific market for rheumatoid arthritis therapeutics reached a value of ... CAGR of over 3.2 percent in the years to come to hit the USD ... by an anticipated launch of a number of promising pipeline candidates and an increase ...
(Date:7/6/2015)... ... July 06, 2015 , ... Cancer Hope Network ... caregivers and medical professionals to chat with the CHN patient services team and ... a cancer diagnosis is often the most traumatic experience of a person’s life,” ...
(Date:7/6/2015)... ... July 06, 2015 , ... In a split second, breaking a ... their risk of having a fracture through the bone health screenings conducted by American ... “We are participating because our residents need this information to remain independent and strong ...
(Date:7/6/2015)... Florida (PRWEB) , ... July 06, 2015 , ... ... solutions, announced today that Randstad Technologies selected Aspect Software Unified IP contact center ... the United States, selected Aspect Unified IP as its future call center platform. ...
(Date:7/5/2015)... ... July 06, 2015 , ... Security Life Insurance ... announce the next generation of PrimeStar Individual Dental Insurance. Beginning now, enhancements include ... network options—Maximum Allowable Charge (MAC) and usual, customary and reasonable (UCR). , ...
Breaking Medicine News(10 mins):Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:National Bone Health Screening and Awareness Day 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 3Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2
... serious public health problem in the United States. Recent data ... injury annually. While the majority of TBIs are concussions or ... number of deaths and cases of permanent disability. ... variety of single drugs have failed clinical trials, suggesting a ...
... , FRIDAY, Sept. 17 (HealthDay News) -- As ... public health organizations are highlighting the need for pregnant ... immunized. "Based on expert medical opinion, we urge ... pregnant, to get their influenza immunization because the flu ...
... of the major public health problems in developed countries", Juan ... at the University of Zaragoza (UNIZAR), tells SINC. "During the ... hours of television per day. At weekends, this figure exceeds ... of the journal Preventive Medicine , show that teenagers ...
... Doheny HealthDay Reporter , THURSDAY, Sept. 16 (HealthDay ... warts, freezing -- also known as cryotherapy -- works better ... study finds. No one treatment cured more than half ... malady are needed, experts say. The new finding is ...
... is recruiting patients for a Phase III lung cancer ... treated patients. The trial will evaluate the potential ... the treatment of Non-Small Cell Lung Cancer (NSCLC). ... Immunotherapy) study is expected to be one of the ...
... Goodwin HealthDay Reporter , THURSDAY, Sept. 16 (HealthDay ... of colorectal cancer, new research finds. Prior research has ... cancer. But this study is among the first to show ... effects such as gastrointestinal bleeding -- may also be effective, ...
Cached Medicine News:Health News:Pregnant Women Urged to Get Flu Shot 2Health News:Pregnant Women Urged to Get Flu Shot 3Health News:Teenagers are more sedentary on weekends 2Health News:For Common Warts, Freezing Therapy Works Best: Study 2Health News:For Common Warts, Freezing Therapy Works Best: Study 3Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 2Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: